Exploiting the Body's Immune System to Treat a Broad Range of Diseases

Read more

ARMO in the News

6/6/2016

ARMO BioSciences’ AM0010 Demonstrates Promising Clinical Data as an Immuno-oncology Monotherapy and in Combination with an Anti-PD-1 Checkpoint Inhibitor in Advanced Solid Tumors, Including Immune-Resistant Cancers  Details